Zhejiang Cancer Hospital
🇨🇳China
Effect of Trendelenburg Positioning on Anesthesia-Induced Hypotension in Elderly Patients
Not Applicable
Not yet recruiting
- Conditions
- Hypotension on InductionOld Age
- First Posted Date
- 2025-05-13
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 168
- Registration Number
- NCT06968091
- Locations
- 🇨🇳
Zhejiang cancer hospital, Hangzhou, Zhejiang, China
Zanubrutinib Plus GCVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisolone) in Previously Untreated Follicular Lymphoma
Phase 2
Not yet recruiting
- Conditions
- BTK InhibitorsFollicular LymphomaImmunochemotherapy
- Interventions
- Drug: ZGCVP
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 58
- Registration Number
- NCT06918015
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
SH-LPS System in Preoperative Planning for Liver Resection
Phase 2
Not yet recruiting
- Conditions
- Liver Tumor; Surgery3D PrintingPreoperative Planning
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06911086
Real World Study of Bone Metastases in Patients with Advanced Breast Cancer
Completed
- Conditions
- Breast Cancer Metastatic
- First Posted Date
- 2025-03-13
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 737
- Registration Number
- NCT06873997
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Zhejiang, China
Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy for EGFR-positive NSCLC Leptomeningeal Metastases
Phase 2
Not yet recruiting
- Conditions
- Leptomeningeal Metastases
- Interventions
- Drug: vometinib
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT06861218
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
The Formulation of Compound Phellinus Igniarius Decoction on Radiation Pneumonitis
Phase 1
Completed
- Conditions
- Radiation Pneumonitis
- Interventions
- Drug: The formulation of Compound Phellinus igniarius decoction
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06861179
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, HangZhou, Zhejiang, China
Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL
Not Applicable
Recruiting
- Conditions
- Primary Central Nervous System Lymphoma
- Interventions
- Drug: Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT)
- First Posted Date
- 2025-02-18
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT06832267
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCL
Not Applicable
Recruiting
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL)
- Interventions
- Drug: Pomalidomide Combination With Rituximab and Anti-PD-1 Antibody （PPR）
- First Posted Date
- 2025-02-18
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06832228
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
To Investigate the Real-world Efficacy and Safety of Sacituzumab Govitecan for HER2 Negative Metastatic Breast Cancer Patients in China.
Not yet recruiting
- Conditions
- Breast Cancer Metastatic
- First Posted Date
- 2025-01-20
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06784921
Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC
Phase 2
Not yet recruiting
- Conditions
- Locally Advanced Nasopharyngeal Carcinoma
- Interventions
- Drug: Experimental drug
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 58
- Registration Number
- NCT06752382
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
© Copyright 2025. All Rights Reserved by MedPath